Insys Therapeutics Inc (NASDAQ:INSY) has been assigned a consensus rating of “Hold” from the eight research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.50.
Several equities research analysts recently commented on INSY shares. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 4th. ValuEngine cut Insys Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 13th. Finally, Janney Montgomery Scott reissued a “buy” rating and issued a $11.00 price target on shares of Insys Therapeutics in a research note on Wednesday, December 19th.
Shares of INSY traded down $0.03 during trading hours on Friday, reaching $4.64. The company’s stock had a trading volume of 5,364 shares, compared to its average volume of 554,012. The company has a market capitalization of $332.73 million, a price-to-earnings ratio of -9.45 and a beta of 2.07. Insys Therapeutics has a 1-year low of $3.35 and a 1-year high of $11.65.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in shares of Insys Therapeutics in the 3rd quarter valued at approximately $113,000. Creative Planning bought a new stake in Insys Therapeutics during the third quarter worth approximately $153,000. Tower Research Capital LLC TRC bought a new stake in Insys Therapeutics during the second quarter worth approximately $131,000. MetLife Investment Advisors LLC bought a new stake in Insys Therapeutics during the third quarter worth approximately $223,000. Finally, BlueMountain Capital Management LLC boosted its position in Insys Therapeutics by 533.6% during the third quarter. BlueMountain Capital Management LLC now owns 28,145 shares of the specialty pharmaceutical company’s stock worth $284,000 after purchasing an additional 23,703 shares during the period. 17.22% of the stock is owned by institutional investors and hedge funds.
About Insys Therapeutics
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Read More: Intrinsic Value and Stock Selection
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.